Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 1:00 p.m. GMT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 1:00 p.m. GMT.
A live webcast will be available via the Investors section of Kyverna's website at ir.kyvernatx.com, and a replay will be posted for approximately 90 days after the conference.
Details
News Market Reaction – KYTX
On Nov 10, the day this news came out, KYTX closed 2.89% below the previous close.
Data tracked by StockTitan Argus for the Nov 10 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Monday, November 17, 2025 at 1:00 p.m. GMT.
A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for approximately 90 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications for the Company to advance into late-stage development. Additionally, its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, including efficiently expanding into broader autoimmune indications and the potential to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process. For more information, please visit https://kyvernatx.com.
Contacts:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.